Archive for the ‘Uncategorized’ Category
February 7th, 2010 | 
Author: Scientists have 
begun to investigate the ability of certain biological components of whey protein to support immunity. Those include: lactoferrin, beta-lactoglobulin, alpha-lactalbumin, glycomacropeptide, and immunoglobulins. Years of scientific research have resulted in the development of a specially designed whey protein that can support immune function, protect against free radical attack, and maintain lean muscle mass.
Life Extension® offers whey protein powders in four flavors that contain added lactoferrin. Life Extension uses a production method that produces a high quality whey protein isolate. Using a low temperature microfiltration technique, it is possible to produce a 98% undenatured whey protein isolate that retains all the important sub-fractions, such as lactoferrin, a strong antioxidant with immune-supporting properties.
Link under the cut.
Posted in 
A dietary regimen that is the opposite of the high protein Atkins diet was associated with a longer lifespan and improved mitochondrial function in research conducted with flies at the Buck Institute for Age Research in Novato, California. Reduced functioning of the mitochondria, which are the power plants of the cells, occurs with aging and is associated with such diseases such as type 2 diabetes and Parkinson’s disease. Read the rest of this entry »
Purely Proteins has been established to exploit the increasing need for and use of human proteins in human medical research. The company purifies suites of human proteins, as both drug targets and bio-therapeutics, using proprietary processes that ensure both high purity and biological activity. Purely Proteins also offers ligand screening services, backed by state-of-the-art informatics, to examine therapeutic targeting to these proteins.
Purely Proteins Ltd (Cambridge, UK) announced today its Board’s decision to accelerate the Company’s internal program to discover and develop proprietary purification processes to selectively purify human serum therapeutics. Together with its existing partnered programs, this new initiative will position the company to offer proprietary products in addition to value-creating services. Initial targets in the Purely Proteins program include the major serum proteins Immunoglobulin G and Alpha-1 Antitrypsin, in addition to specific human growth factors and infectious agents. In the latter category, specific focus will be on viruses and prion proteins that pose major health threats and offer significant market opportunities for innovative products. The market for human Alpha-1 Antitrypsin alone is projected to grow to $1 billion by 2010, while IgG therapeutics already represent a significant proportion of today’s $26 billion biotherapeutic market.